NeuroSense Therapeutics Files 6-K with Financials
Ticker: NRSNW · Form: 6-K · Filed: Sep 30, 2024 · CIK: 1875091
Sentiment: neutral
Topics: financials, 6-K, reporting
TL;DR
NeuroSense dropped its Q2 2024 financials in a 6-K filing.
AI Summary
NeuroSense Therapeutics Ltd. filed a Form 6-K on September 30, 2024, reporting its condensed interim unaudited financial statements as of June 30, 2024. The filing also includes a summary of its operating and financial review and prospects.
Why It Matters
This filing provides investors with an update on NeuroSense Therapeutics' financial position and operational outlook as of mid-2024.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain new material events or significant changes.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Registrant
- June 30, 2024 (date) — Financial statement date
- September 30, 2024 (date) — Filing date
FAQ
What type of financial statements are included in this 6-K filing?
The filing includes condensed interim unaudited financial statements as of June 30, 2024.
What is the primary purpose of this Form 6-K filing?
The purpose is to report foreign private issuers' information, specifically attaching the company's condensed interim unaudited financial statements and a summary of its operating and financial review and prospects.
When is the period of report for the financial statements?
The conformed period of report is June 30, 2024.
What is the company's principal executive office address?
The principal executive office is located at 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
Does NeuroSense Therapeutics file annual reports under Form 20-F or 40-F?
NeuroSense Therapeutics indicates it files annual reports under Form 20-F.
Filing Stats: 320 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2024-09-30 16:53:49
Filing Documents
- ea0216145-6k_neurosense.htm (6-K) — 16KB
- ea021614501ex99-1_neurosense.htm (EX-99.1) — 199KB
- ea021614501ex99-2_neurosense.htm (EX-99.2) — 85KB
- ex99-2_001.jpg (GRAPHIC) — 19KB
- 0001213900-24-083414.txt ( ) — 1813KB
- nrsn-20240630.xsd (EX-101.SCH) — 25KB
- nrsn-20240630_cal.xml (EX-101.CAL) — 20KB
- nrsn-20240630_def.xml (EX-101.DEF) — 93KB
- nrsn-20240630_lab.xml (EX-101.LAB) — 207KB
- nrsn-20240630_pre.xml (EX-101.PRE) — 101KB
- ea0216145-6k_neurosense_htm.xml (XML) — 105KB
Financial Statements as of June 30, 2024
Financial Statements as of June 30, 2024 99.2 Operating and Financial Review and Prospects as of June 30, 2024 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Label Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Presentation Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Definition Linkbase Document 104 Cover Page Interactive Data File formatted as Inline XBRL and contained in Exhibit 101 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: September 30, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 3